1. INTRODUCTION 1
2. LITERATURE REVIEW 7
2.1 Central Nervous System 7
2.2 Barriers to CNS Drug Delivery 8
2.3 Physicochemical factors responsible for brain uptake 11
2.4 Drug delivery approaches for brain-targeting 12
2.5 Nanoparticles for delivery across BBB 15
2.6 Receptor mediated transport through transferrin receptors 25
2.7 Intranasal Drug Delivery 30
2.8 Brain Tumor 33
2.9 Drug Profile 36
2.9.1 Etoposide 36
2.9.2 Temozolomide 39
References 46
3. ANALYTICAL METHODS 52
3.1 Estimation of Etoposide 54
3.1.1 Estimation of Etoposide in solution 54
3.1.2 Estimation of Etoposide in NPs 57
3.1.3 Estimation of Etoposide for in-vitro release 57
3.2 Estimation of Temozolomide 58
3.2.1 Estimation of Temozolomide in solution 58
3.2.2 Estimation of Temozolomide in NPs 61
3.2.3 Estimation of Temozolomide for in-vitro release 61
3.3. Estimation of 6-Coumarin 61
3.3.1 Estimation of 6-coumarin in solution 61
3.3.2 Estimation of 6-coumarin in NPs 64
3.4 Estimation of residual PVA 64
3.5 Determination of protein (transferrin) by BCA method 66
3.6 Determination of Particle Size, Polydispersity and Zeta potential 69

3.7 Morphological characterization 69
3.8 Differential scanning calorimetry 70
3.9 Discussion 71
References 73
4.PREPARATION AND TRANSFERRIN CONJUGATION OF NANOPARTICLES . 74
4.1 Introduction 74
4.2 Methods 78
4.2.1 Preparation and optimization of nanoparticles 78
4.2.2 Lyophilization and optimization of cryoprotectant concentration 94
4.2.3 Transferrin conjugation of nanoparticles 94
4.2.4 Preparation of 6-coumarin loaded nanoparticles 96
4.3 Results and Discussion 97
4.3.1 Preparation and optimization of nanoparticles 97
4.3.2 Lyophilization and optimization of cryoprotectant concentration 103
4.3.3 Transferrin conjugation of nanoparticles 105
4.4 Conclusions 113
References 114
5. CHARACTERIZATION OF NANOPARTICLES 117
5.1 Introduction 117
5.2 Methods 119
5.2.1. Particle size, zeta potential and drug entrapment efficiency 119
5.2.2. In-vitro drug release 119
5.2.3. Transmission electron microscopy 120
5.2.4 Differential Scanning Calorimetry 120
5.2.5 Residual PVA 121
5.2.6 Characterization of 6-coumarin nanoparticles 121
5.3 Results and Discussions 122
5.3.1 Particle size, zeta potential and drug entrapment efficiency 122
5.3.2 In-vitro Drug Release 125
5.3.3 Transmission Electron Microscopy 127
5.3.4 Differential Scanning Calorimetry 128

5.3.5 Residual PVA 131
5.3.6 Characterization of 6-coumarin nanoparticles 131
5.4 Conclusions 132
References 133
6. STABILITY STUDIES 134
6.1 Introduction 134
6.2 Methodology 135
6.3 Results and Discussion 137
6.4 Conclusions 148
References 149
7. IN-VITRO CELL CULTURE STUDIES 150
7.1 Introduction 150
7.2 Method 152
7.2.1 Intracellular uptake studies 152
7.2.3 In-vitro Cytotoxicity Studies 153
7.3 Results and Discussion 155
7.3.1 Intracellular uptake of Nanoparticles 155
7.3.2 Fluorescent microscopy 159
7.3.3 In-vitro Cytotoxicity Studies 161
7.4 Conclusions 171
References 172
8. RADIOLABELING OF FORMULATIONS 174
8.1 Introduction 174
8.2 Methods 178
8.2.1 Radiolabeling of Etoposide Formulations 178
8.2.2 Radiolabeling of Temozolomide Formulations 182
8.3 Discussions 186
References 188
9. IN-VIVO BIODISTRIBUTION STUDIES 189
9.1 Methods 189
9.1.1 Animals 189

9.1.2 Biodistribution and Pharmacokinetic Studies of ETP formulations.....189
9.1.3 Biodistribution and Pharmacokinetic studies of TMZ formulations.....190
9.2 Result and Discussion.....191
9.2.1 Biodistribution and Pharmacokinetic Studies of ETP formulations.....191
9.2.2 Biodistribution and Pharmacokinetic Studies of TMZ formulations.....200
9.3 Conclusions.....208
References.....209
10. SUMMARY AND CONCLUSIONS.....211